Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Hires Chiron Executive as President Of Predictive Medicine

Premium

CAMBRIDGE, Mass.--Millennium Pharmaceuticals here has named Kenneth Conway to the position of president of predictive medicine, where he will lead a new initiative to develop genomics-derived products and services to predict, diagnose and monitor disease and drug response. Conway was previously senior vice-president and general manager of immuno diagnostics for Chiron Diagnostics, and had held several other executive positions with that company.

Nick Galakatos, Millennium's vice-president of new businesses, commented, "His appointment is consistent with Millennium's commitment to leverage its technology and retained rights by creating a family of new businesses." Millennium employs large-scale genetics, genomics, high-throughput screening, and bioinformatics to assist in the discovery and development of therapeutic and diagnostic products.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.